
Proximately 1% of extranodal lymphomas, and there are less well tolerated, and, at the time of writing, response to it is pending evaluation.

Row infiltration was found. Chemotherapy was started and lymph 90% and P53 positive in approximately 80%. No bone marrow infiltration was found. Following glucocorticoid replacement therapy, laparotomy was performed, at which a biopsy could only be performed because both lesions were surgically non-resectable. A pathological study reported a large diffuse B-cell non-Hodgkin lymphoma, CD20 positive and Ki-67 positive in approximately 80%. No bone marrow infiltration was found. Chemotherapy was started and well tolerated, and, at the time of writing, response to it is pending evaluation.

Primary lymphoma of the adrenal gland accounts for approximately 1% of extranodal lymphomas, and there are less than 100 tumors of this type reported in the literature. It is more common in males than in females (2:1), and mean age at tumor occurrence is approximately 68 years. Bilateral adrenal involvement is found in 65% of cases. Ninety percent of PALs are large B-cell non-Hodgkin lymphomas, but insufficiency is usually subclinical in most of them.

Despite its low incidence, PAL should be included in differential diagnosis of an adrenal gland together with other malignant tumors such as carcinoma of the breast and lung, gastrointestinal tract tumors, and malignant melanoma, in which the incidence of adrenal metastases, often bilateral, is high. Differential diagnosis should also include other con-
ditions such as primary adrenal carcinoma, pheochromocytoma, and some infectious conditions.

PAL is the disease with the poorest prognosis among extranodal B-cell lymphomas. Ninety percent of reported patients die within one year of diagnosis despite treatment. The chemotherapy schemes routinely used with curative intent for the treatment of high-grade B lymphomas provide very poor results in PAL. Radiotherapy may improve local control of the disease, but its impact on the survival of these patients is unknown. Finally, glucocorticoid replacement therapy should be part of the treatment when some degree of adrenal insufficiency exists.

References


Ignacio Rasero Hernández, Rafael Hernández Lavado*, Pilar Rodríguez Ortega, Carlos Guzmán Carmona, José Díaz Pérez de Madrid

Sección de Endocrinología y Nutrición, Hospital Infanta Cristina, Badajoz, Spain

*Corresponding author.
E-mail address: hernandezlavado@eresmas.com (R. Hernández Lavado).